An update is available for this article. Background: The prevalence of osteoporosis is
increasing in the United States. Purpose: To evaluate low bone mass and osteoporosis …

Abstract Introduction: The American Thyroid Association appointed a Task Force of experts
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …

Background Bisphosphonates are effective in reducing hip and osteoporotic fractures.
However, concerns about atypical femur fractures have contributed to substantially …

Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures.
Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the …

Reports linking long‐term use of bisphosphonates (BPs) with atypical fractures of the femur
led the leadership of the American Society for Bone and Mineral Research (ASBMR) to …

To treat systemic bone loss as in osteoporosis and/or focal osteolysis as in rheumatoid
arthritis or periodontal disease, most approaches target the osteoclasts, the cells that resorb …

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal
women with osteoporosis. To investigate long‐term effects of ZOL on bone mineral density …

Background Studies show conflicting results regarding the possible excess risk of atypical
fractures of the femoral shaft associated with bisphosphonate use. Methods In Sweden …

Women may expect to spend more than a third of their lives after menopause. Beginning in
the sixth decade, many chronic diseases will begin to emerge, which will affect both the …

Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip,
vertebral, and other fractures by as much as 50% to 70%. However, since 2006, atypical …